WP
COLL icon

Woodline Partners’s Collegium Pharmaceutical COLL Stock Holding History

Woodline Partners’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.61M Buy
+72,139
New +$2.47M 0.01% 808

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Woodline Partners's COLL Position: Q2 2026 in Review

Woodline Partners opened a new position in Collegium Pharmaceutical (COLL) in Q2 2026: 72,139 shares worth $2.61M. The stake represents 0.01% of the portfolio and ranks #808 among its holdings.

279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Woodline Partners held 72,139 shares of Collegium Pharmaceutical worth $2.61M as of Q2 2026.
  • Collegium Pharmaceutical was a new Woodline Partners position in Q2 2026.
  • Collegium Pharmaceutical made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #808 holding.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.